I’ve been relatively quiet until I saw this. You'd think management would consider a simultaneous 5 country launch of a product to be important enough to not burry in a MD&A discussion.
With that I leave you guys for the next few months to control the bullboard.
In the corporate update press release:
EAA Launch Q4 2020:
The Company is currently in the market planning phase, collaborating with one of its distribution partners on a multi-country European launch of EAA at the beginning of Q4 2020. Spectral’s distribution partner currently anticipates a simultaneous launch in five countries in western Europe. The Company is pleased with the efforts and engagement of its distribution partner and looks forward to continue working with its partner to launch EAA in other potential new markets.
Burried in the MD&A
"The Company also continues to sell its EAATM diagnostic under the terms of existing commercial arrangements. Previously, the Company anticipated a multi country launch of EAATM with an existing distribution partner in mid Q4 2020, which now has been delayed. Proprietary reagents continue to sell under regular purchase orders as issued by customers. The Company is continuing its efforts in the commercialization of SAMI as well as the development and commercialization of DIMI."